Aldeyra Therapeutics closed at $0.65 on Nov 4, up 4.32%, 88.5% below its 52-week closing high. Volume of 1.0M shares was 1.01× its 20-day average (close to normal).
Split-adjusted performance: -29.3% over one month, -62.8% over six months, -87.6% over one year.
Short interest was 3.2M shares at the Oct 15 settlement, down 8.2% from the prior report (6.0% of float, 1.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ALDXAldeyra Therapeutics | $0.6474 | +4.32% | −62.8% | — | — | — | $39.1M | |
| DWTXDogwood Therapeutics | $1.03 | −0.96% | −37.6% | — | — | — | $39.4M | Compare |
| SCYXSCYNEXIS | $3.84 | −2.54% | −51.1% | −82.8% | 3147.7% | — | $38.2M | Compare |
| GRCEGrace Therapeutics | $1.81 | −1.63% | −23.6% | — | — | — | $38.1M | Compare |
| VERUVeru | $2.20 | +1.85% | −0.9% | — | — | — | $37.5M | Compare |
| ELTXElicio Therapeutics | $1.56 | +2.63% | −85.1% | — | — | — | $42.3M | Compare |
| SERSerina Therapeutics | $1.69 | −7.65% | −7.7% | −100.0% | — | — | $42.9M | Compare |
| BTMDBiote | $1.23 | +9.82% | −44.1% | −9.5% | −14.8% | 6.0 | $35.3M | Compare |
| NNVCNanoViricides | $1.38 | −3.50% | −5.5% | — | — | — | $35.2M | Compare |
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
